Anti-hip fracture efficacy of bisphosphonates: A Bayesian analysis of clinical trials

Journal of Bone and Mineral Research

Volumn 21, Issue 2, 2006, Pages 340-349

  Nguyen, Nguyen D ^b   Eisman, John A ^b   Nguyen, Tuan V ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b NONE

Author keywords

Alendronate; Bayesian approach; Bisphosphonates; Clodronate; Etidronate; Hip fracture; Meta analysis; Osteoporosis; Postmenopause; Risedronate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CALCIUM CARBONATE; CLODRONIC ACID; ETIDRONIC ACID; PLACEBO; RISEDRONIC ACID; VITAMIN D;

BAYES THEOREM; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; HIP FRACTURE; HUMAN; META ANALYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; SEQUENTIAL ANALYSIS; SYSTEMATIC REVIEW;

BAYES THEOREM; DIPHOSPHONATES; FEMALE; HIP FRACTURES; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33144467841     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.050903     Document Type: Review

References (40)

1. Cummings SR, Black DM, Rubin SM 1989 Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 149:2445-2448.
2. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA 1999 Mortality after all major types of osteoporotic fracture in men and women: An observational study. Lancet 353:878-882.
3. Banks E, Beral V, Reeves G, Balkwill A, Barnes I 2004 Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA 291:2212-2220.
4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333.
5. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C 2002 Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570-578.
6. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541.
7. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437-1443.
8. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340.
9. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83-91.
10. Papapoulos SE, Quandt SA, Liberman UA, Hochberg MC, Thompson DE 2004 Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 16:468-474.
11. DerSimonian R, Laird N 1986 Meta-analysis in clinical trials. Control Clin Trials 7:177-188.
12. Sutton AJ, Abrams KR 2001 Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res 10:277-303.
13. Warn DE, Thompson SG, Spiegelhalter DJ 2002 Bayesian random effects meta-analysis of trials with binary outcomes: Methods for the absolute risk difference and relative risk scales. Stat Med 21:1601-1623.
14. Spiegelhalter DJ, Thomas A, Best NJ 1999 WinBUGS Version 1.2 User Manual. Available online at http://www.mrc-bsu .cam.ac.uk/bugs/winbugs/contents.shtml. Accessed March 25, 2004.
15. Cochran WG 1954 The combination of estimates from different experiments. Biometrics 10:101-129.
16. Higgins JP, Thompson SG 2002 Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558.
17. Macaskill P, Walter SD, Irwig L 2001 A comparison of methods to detect publication bias in meta-analysis. Stat Med 20:641-654.
18. Diamond GA, Kaul S 2004 Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials. J Am Coll Cardiol 43:1929-1939.
19. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280:2077-2082.
20. Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B 1999 Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 9:461-468.
21. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352.
22. McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkanen L, Kenraali J, Aropuu S, Kanis JA 2004 Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: Results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 19:728-736.
23. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH 1990 Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271.
24. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnut CH III 1993 Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Med 95:557-567.
25. Greenspan SL, Schneider DL, McClung MR, Miller PD, Schnitzer TJ, Bonin R, Smith ME, DeLucca P, Gormley GJ, Melton ME 2002 Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 136:742-746.
26. Bonnick SL, Rosen C, Mako B, DeLucca P, Byrnes C, Melton ME 1998 Alendronate vs Calcium for Treatment of Osteoporosis in Postmenopausal Women. Bone 23(Suppl 5):S476-S477.
27. Miller PD, Watts NB, Licata AA, Harris ST, Genant HK, Wasnich RD, Ross PD, Jackson RD, Hoseyni MS, Schoenfeld SL, Valent DJ, Chesnut CH III 1997 Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment. Am J Med 103:468-476.
28. Pouilles JM, Tremollieres F, Roux C, Sebert JL, Alexandre C, Goldberg D, Treves R, Khalifa P, Duntze P, Horlait S, Delmas P, Kuntz D 1997 Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy. Osteoporos Int 7:213-218.
29. Wimalawansa SJ 1998 A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 104:219-226.
30. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC III, Yanover MJ 1990 Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79.
31. Tan SB, Dear KB, Bruzzi P, Machin D 2003 Strategy for randomised clinical trials in rare cancers. BMJ 327:47-49.
32. Lilford RJ, Thornton JG, Braunholtz D 1995 Clinical trials and rare diseases: A way out of a conundrum. BMJ 311:1621-1625.
33. Etzioni RD, Kadane JB 1995 Bayesian statistical methods in public health and medicine. Annu Rev Public Health 16:23-41.
34. Harrell FE Jr, Shih YC 2001 Using full probability models to compute probabilities of actual interest to decision makers. Int J Technol Assess Health Care 17:17-26.
35. Lilford RJ 2003 Ethics of clinical trials from a bayesian and decision analytic perspective: Whose equipoise is it anyway? BMJ 326:980-981.
36. Goodman SN 1999 Toward evidence-based medical statistics. 1: The P value fallacy. Ann Intern Med 130:995-1004.
37. Goodman SN 1999 Toward evidence-based medical statistics. 2: The Bayes factor. Ann Intern Med 130:1005-1013.
38. Goodman SN 1999 Probability at the bedside: The knowing of chances or the chances of knowing? Ann Intern Med 130:604-606.
39. McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH III, Ensrud KE, Burdeska A, Mills T 2004 Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res 19:11-18.
40. Clark WF, Garg AX, Blake PG, Rock GA, Heidenheim AP, Sackett DL 2003 Effect of awareness of a randomized controlled trial on use of experimental therapy. JAMA 290:1351-1355.